N-Acetyl Semax Amidate
Research OnlyA chemically modified version of Semax with N-terminal acetylation and C-terminal amidation designed to enhance peptide stability. While parent Semax is approved in Russia for nootropic and neuroprotective applications, this specific modification has no independent clinical research.
NA-Semax · N-Acetyl Semax · Acetyl-Semax-Amidate · NASA-Semax
Preclinical evidence only
- Preclinical
- 100%
- Clinical
- 0%
Based on 2 cited sources
community-reported · not clinically demonstrated · very-low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 3: ZERO studies exist on N-Acetyl Semax Amidate itself — every cited paper is the parent Semax (16996037, 17353092, 15088389, 29798983) or a generic peptide-stability analogue (thymopentin, 3031628). 1A/1B/1C/1E all near-floor because no human, animal, or in-vitro data exist for this molecule; 1D=2 (evidence only indirect, a different compound). Mechanism 20: 2A=10 (target inferred from parent, no binding data on the modified form), 2B=8 (Semax BDNF/TrkB pathway borrowed, not confirmed for this analogue), 2C=0 (no dose-response), 2D=2 (predicted/extrapolated only). Plausibility 57: 3A=15 (modification preserving Semax activity is a plausible but unproven link), 3B=20 (N-acetylation/C-amidation protease resistance is established chemistry — 3031628 — coherent with Semax biology), 3C=14 (parent Semax is a same-class agent showing the effect), 3D=8 (moderately broad — BDNF, dopamine, serotonin, NGF/GDNF all asserted). Global Coverage 0: no studies of this specific compound to replicate, no geographic breadth, <5 studies, no governance review of the modified form. Community Experience 40: 5A=12 (niche but persistent nootropic-community use), 5B=9 (~1-3 yr track record for the modified form), 5C=12 (broadly consistent "stronger/longer than Semax" reports), 5D=7 (isolated overstimulation/anxiety/hair-loss reports, no serious recurring signal). Effectiveness basis community-reported (very-low), capped at 50: CR1=11 moderate consistent benefit, CR2=11 broadly consistent, CR3=6 single-cluster nootropic discussion — no human efficacy data exist for this compound.
The proposed mechanisms of N-Acetyl Semax Amidate are extrapolated entirely from parent compound Semax research. No direct studies exist on this modified form.
How It Works (Simplified)
N-Acetyl Semax Amidate is proposed to work through the same pathways as Semax, with enhanced stability from terminal modifications:
Parent Semax increases BDNF, NGF, and GDNF expression. Whether modifications preserve this activity is unknown.
Semax affects dopamine and serotonin systems. The modified form’s receptor affinity has never been tested.
Semax activates TrkB receptors for neuroplasticity. Impact of terminal modifications on binding is uncharacterized.
N-acetylation blocks aminopeptidases, C-amidation blocks carboxypeptidases. Actual half-life extension not measured.
Key Research: Dolotov OV et al. (Russia, 2006) demonstrated BDNF and TrkB expression effects with Semax in the rat hippocampus. PMID:16996037
Important Limitations
- Zero published studies on N-Acetyl Semax Amidate specifically
- All mechanisms extrapolated from parent Semax research
- Whether modifications preserve biological activity is untested
- No human pharmacokinetic data exists for this compound
Reported positives
- Stronger and longer-lasting than standard semax reported
- Enhanced cognitive stimulation and focus
- Modified form provides improved bioavailability
- Nasal administration convenient
Reported negatives
- Overstimulation and anxiety at higher amounts
- More expensive than standard semax
- Hair loss concerns carried over from semax reports
- Limited supplier options
“Considered the potent version of semax. Popular in nootropic stacks.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
No human data available. Based on parent Semax pharmacology: Acute cognitive effects may be noticed. Russian Semax studies suggest rapid onset of action. Whether modifications alter timeline is unknown.
PMID:16996037Extrapolated from Semax: Neurotrophic factor expression changes may develop. Parent compound shows BDNF modulation in animal models within this timeframe. No data specific to NA-Semax-Amidate.
PMID:17353092Based on general nootropic peptide research: Neuroplasticity effects may accumulate with continued use. No long-term studies exist for this modified compound.
PMID:15088389Completely unknown. No studies have evaluated extended use of N-Acetyl Semax Amidate. Long-term safety and efficacy data do not exist.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Semax
SynergisticParent compound with identical core sequence. NA-Semax-Amidate is designed to extend duration of action through terminal modifications. No studies comparing direct combination.
Na-Selank-Amidate
CompatibleBoth are modified Russian nootropic peptides with different mechanisms (Semax: neurotrophic focus vs Selank: anxiolytic focus). Commonly discussed together but no interaction studies exist.
Selank
CompatibleDifferent mechanism profiles. Selank focuses on anxiolytic effects while Semax derivatives target cognitive enhancement. No known contraindications.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare N-Acetyl Semax Amidate
Related Peptides
Alixorexton
ALKS 2680 · ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070 · N-PEP-12 · Renacenz
Cerebrolysin is a porcine brain-derived peptide mixture approved in 50+ countries for stroke, dementia, and traumatic brain injury. It is NOT FDA-approved in the United States despite decades of international clinical use. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. Mixed Phase 3 results but positive meta-analyses and widespread adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin · Cerebral peptides · A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum · Polypeptide brain extract · Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide · Delta Sleep-Inducing Peptide · WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.